United Therapeutics Corporation (UTHR)

Return on equity (ROE)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	984,800	899,800	871,500	728,300	727,300	707,400	630,800	687,400	475,800	462,400	470,900	405,400	514,800	698,300	659,500	757,500	125,200	192,400	166,500	134,300
Total stockholders’ equity	US$ in thousands	5,984,800	5,712,100	5,411,000	5,123,200	4,796,700	4,562,200	4,318,400	4,176,300	3,958,900	3,829,700	3,639,500	3,445,400	3,395,200	3,283,100	3,093,700	2,948,500	2,780,400	2,715,800	2,558,400	2,319,000
ROE		16.46%	15.75%	16.11%	14.22%	15.16%	15.51%	14.61%	16.46%	12.02%	12.07%	12.94%	11.77%	15.16%	21.27%	21.32%	25.69%	4.50%	7.08%	6.51%	5.79%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $984,800K ÷ $5,984,800K
= 16.46%

To analyze United Therapeutics Corp's return on equity (ROE) over the past few quarters, we observe a relatively stable performance with small fluctuations. The ROE ranged between 14.22% and 16.46% throughout the eight quarters displayed. The company seems to have maintained a consistent ability to generate profit from shareholders' equity during this period.

The highest ROE of 16.46% was recorded in Q4 2023, indicating that the company was able to generate a solid return on the shareholder's equity during that quarter. On the other hand, the lowest ROE of 14.22% was recorded in Q1 2023, representing a slight dip in profitability compared to other quarters.

Overall, United Therapeutics Corp's ROE performance indicates that the company has been effectively utilizing its equity to generate profits for its shareholders, showcasing stability and efficiency in its operations.